Abstract
The rapid succession of new variants of SARS-CoV-2 emphasizes the need to understand the factors driving pathogen evolution. Here, we investigate a possible tradeoff between the rate of progression of a disease and its reproductive number. Using an SEIR framework, we show that in the exponential growth phase of an epidemic, there is an optimal disease duration that balances the advantage of a fast disease progression with that of causing many secondary infections. This result offers one possible explanation for the ever shorter generation times of novel variants of SARS-CoV-2, as it progressed from the original strain to the Alpha, Delta, and, from late 2021 onwards, to several Omicron variant subtypes. In the endemic state, the optimum disappears and longer disease duration becomes advantageous for the pathogen. However, selection pressures depend on context: mitigation strategies such as quarantine of infected individuals may slow down the evolution towards longer-lasting, more infectious variants. This work then suggests that, in the future, the trend towards shorter generation times may reverse, and SARS-CoV-2 may instead evolve towards longer-lasting variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KS and AE have received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 740704). BFN received funding from the Carlsberg Foundation under its Semper Ardens programme (grant no. CF20-0046), and AE received funding from NordForsk under the Nordic Programme for Interdisciplinary Research (grant no. 104910).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updates made in response to reviewer comments. Most notably, Table 1 and Fig. 4 have been changed, and the section on endemic state dynamics has been expanded.
Data Availability
The code used to generate the plots shown in this article is available on GitHub under the URL https://github.com/gks973/Evolution_of_speed or in a permanent archived version at https://doi.org/10.5281/zenodo.7512664.
